MG
SLDB icon

Michael Gelband’s Solid Biosciences SLDB Stock Holding History

Michael Gelband’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-62,801
Closed -$438K – 2000
2024
Q3 		$438K Buy
62,801
+27,971
+80% +$227K ﹤0.01% 1239
2024
Q2 		$197K Buy
34,830
+10,745
+45% +$96.2K ﹤0.01% 1398
2024
Q1 		$321K Buy
+24,085
New +$225K ﹤0.01% 1247
2022
Q1 		– Sell
-4,272
Closed -$112K – 2634
2021
Q4 		$112K Buy
4,272
+2,673
+167% +$81.7K ﹤0.01% 1941
2021
Q3 		$57K Sell
1,599
-547
-25% -$23.2K ﹤0.01% 1964
2021
Q2 		$118K Buy
2,146
+592
+38% +$39.1K ﹤0.01% 2116
2021
Q1 		$129K Sell
1,554
-1,505
-49% -$167K ﹤0.01% 1947
2020
Q4 		$348K Buy
+3,059
New +$193K ﹤0.01% 1460

Other funds holding SLDB

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $2.8B AUM 13.35% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Michael Gelband's SLDB Position: Q4 2024 in Review

Michael Gelband sold out of Solid Biosciences (SLDB) in Q4 2024, closing a stake of 62,801 shares — an estimated $438K sold.

Michael Gelband first reported a position in SLDB in Q4 2020 and held it in 8 quarters. The position peaked at $438K in Q3 2024. 90 funds tracked by Wall St. Rank hold SLDB as of Q4 2024.

  • Michael Gelband reported no remaining Solid Biosciences position as of Q4 2024 after selling out during the quarter.
  • Michael Gelband sold 62,801 Solid Biosciences shares in Q4 2024, an estimated $438K.
  • Michael Gelband first reported a position in Solid Biosciences in Q4 2020 and held it in 8 quarters.
  • Michael Gelband's Solid Biosciences position peaked at $438K in Q3 2024.
  • 90 funds tracked by Wall St. Rank held Solid Biosciences as of Q4 2024.

Based on ExodusPoint Capital Management's 13F filing for Q4 2024, filed 12 Feb 2025.